R Stasi

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi request reprint Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use
    Maria Laura Evangelista
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Curr Drug Discov Technol 4:162-73. 2007
  2. doi request reprint Eltrombopag for the treatment of idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, Albano Laziale, Italy
    Expert Rev Hematol 1:145-52. 2008
  3. ncbi request reprint Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Am J Med 118:414-9. 2005
  4. ncbi request reprint Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Leuk Lymphoma 46:509-16. 2005
  5. ncbi request reprint Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Oncologist 10:539-54. 2005
  6. ncbi request reprint Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Ann Oncol 16:1921-7. 2005
  7. pmc Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
    PLoS Med 3:e24. 2006
  8. ncbi request reprint Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via San Francesco, 50, 00041 Albano Laziale, Italy
    Rheumatology (Oxford) 45:1432-6. 2006
  9. ncbi request reprint Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Italy
    Blood 110:2924-30. 2007
  10. ncbi request reprint Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Regina Apostolorum Hospital, Via S Francesco, 50, Albano Laziale, Italy
    Cancer Treat Rev 34:49-60. 2008

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use
    Maria Laura Evangelista
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Curr Drug Discov Technol 4:162-73. 2007
    ..The aim of the present review is to illustrate the biology of TPO and its receptor, and to describe the structure and function of the new thrombopoietic agents...
  2. doi request reprint Eltrombopag for the treatment of idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, Albano Laziale, Italy
    Expert Rev Hematol 1:145-52. 2008
    ..Ongoing studies will reveal the potential of this agent in the management of immune thrombocytopenia for long-term maintenance therapy, as well as its relative benefit compared with standard-of-care treatment...
  3. ncbi request reprint Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Am J Med 118:414-9. 2005
    ..To investigate the relation between Helicobacter pylori infection and the clinical features of idiopathic thrombocytopenic purpura (ITP), and to examine the effects of H. pylori eradication on platelet counts...
  4. ncbi request reprint Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Leuk Lymphoma 46:509-16. 2005
    ..Further studies are currently underway and should provide useful information to define the more responsive subtypes of MDS, the patient characteristics, and the proper dosing regimen...
  5. ncbi request reprint Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Oncologist 10:539-54. 2005
    ..A stronger methodology for clinical studies and the design of new, randomized, clinical trials is a major priority...
  6. ncbi request reprint Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Ann Oncol 16:1921-7. 2005
    ..The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS)...
  7. pmc Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
    PLoS Med 3:e24. 2006
    ..The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown...
  8. ncbi request reprint Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via San Francesco, 50, 00041 Albano Laziale, Italy
    Rheumatology (Oxford) 45:1432-6. 2006
    ..We prospectively studied the long-term effects of rituximab in 10 patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis refractory to conventional therapy (n=3) or in second or subsequent relapse (n=7)...
  9. ncbi request reprint Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Italy
    Blood 110:2924-30. 2007
    ..Our findings indicate that in patients with ITP, response to B-cell depletion induced by rituximab is associated with significant changes of the T-cell compartment...
  10. ncbi request reprint Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Regina Apostolorum Hospital, Via S Francesco, 50, Albano Laziale, Italy
    Cancer Treat Rev 34:49-60. 2008
    ..Combinations of GO with chemotherapy as induction or post-remission therapy are promising, and phase III trials are ongoing...
  11. doi request reprint Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management
    Roberto Stasi
    Department of Medical Sciences, Ospedale, Regina Apostolorum Hospital, Albano Laziale, Italy
    Thromb Haemost 99:4-13. 2008
    ..This review will focus on the pathophysiology and treatment of ITP in adults, highlighting recent advances in both fields...
  12. ncbi request reprint Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
    Roberto Stasi
    Regina Apostolorum Hospital, Department of Medical Sciences, Via S Francesco, 50, 00041 Albano Laziale, Italy
    Expert Opin Biol Ther 8:527-40. 2008
    ..Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody...
  13. doi request reprint Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
    Blood 112:1147-50. 2008
    ..These results indicate that patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell-targeted therapy...
  14. ncbi request reprint Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Italy
    Drugs 68:901-12. 2008
    ..Ongoing phase III clinical trials will reveal the potential of these agents in the management of ITP prior to splenectomy and for long-term maintenance therapy, as well as their relative benefit compared with standard of care treatment...
  15. doi request reprint Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco, Albano Laziale 5000041, Italy
    Med Oncol 26:22-6. 2009
    ..We conclude that differential therapeutic strategies based on the risk of relapse associated with the International Prognostic Index (IPI) are a reasonable way to approach PBL, and can avoid undue toxicity deriving from treatment...
  16. ncbi request reprint Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Ann Oncol 15:1684-90. 2004
    ..We performed a clinical trial to evaluate the effects of this new dosing regimen in patients with MDS who were unresponsive to the conventional three-times-weekly schedule...
  17. ncbi request reprint Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Blood 103:4424-8. 2004
    ..A reinforcement of therapy with other agents seems to be required to achieve a full and durable response in those patients with high inhibitor levels...
  18. doi request reprint Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Italy
    Blood 113:1231-40. 2009
    ..These findings suggest that the detection and eradication of H pylori infection should be considered in the work-up of patients with seemingly typical ITP...
  19. ncbi request reprint Response to recombinant human erythropoietin in patients with myelodysplastic syndromes
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, 00041 Albano Laziale, Italy
    Clin Cancer Res 3:733-9. 1997
    ..These data suggest that rhEPO has a role in the treatment of certain patients with MDS, particularly in those with a high erythroid index and detectable circulating erythroid burst-forming units...
  20. ncbi request reprint Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Via S Francesco 50, 00041 Albano Laziale, Italy
    Blood Cells Mol Dis 26:582-6. 2000
    ..We conclude that high-dose DXM has a limited effect in patients with chronic ITP. Novel approaches and controlled multicenter trials may help identify new therapeutic strategies for this disease...
  21. ncbi request reprint Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Br J Haematol 105:141-8. 1999
    ..However, in vivo synergy between these growth factors for the production of erythroid precursors is not supported by our data...
  22. ncbi request reprint Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Blood 98:952-7. 2001
    ..In view of its mild toxicity and the lack of effective alternative treatments, its use in the setting of chronic refractory ITP is warranted. (Blood. 2001;98:952-957)..
  23. ncbi request reprint Management of immune thrombocytopenic purpura in adults
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Mayo Clin Proc 79:504-22. 2004
    ..We describe a logical and structured approach to the clinical management of ITP in adults, based on a literature review and our personal experience...
  24. ncbi request reprint Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Am J Med Sci 315:237-41. 1998
    ..We conclude that subcutaneous human leukocyte interferon-alpha is an effective and well-tolerated therapy in the management of polycythemia vera-associated myeloproliferation and pruritus in patients less than 60 years old...
  25. ncbi request reprint AML-M0: a review of laboratory features and proposal of new diagnostic criteria
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Blood Cells Mol Dis 25:120-9. 1999
    ..In this article we review the laboratory data acquired from various sources and suggest a partial modification of diagnostic criteria...
  26. ncbi request reprint Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Br J Haematol 116:334-7. 2002
    ..Laboratory studies indicated a remarkable decrease in the percentage of apoptotic stem cells in the bone marrow. This preliminary report indicates that infliximab may have an application as MDS therapy and warrants further investigation...
  27. ncbi request reprint Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Ita
    S Amadori
    Department of Hematology, University Tor Vergata, Rome, Italy
    Leukemia 19:1768-73. 2005
    ..05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted...
  28. ncbi request reprint [Anemia induced by solid tumor chemotherapy]
    Roberto Stasi
    Dipartimento di Scienze Mediche, Ospedale Regina Apostolorum, Albano Laziale
    Recenti Prog Med 93:585-601. 2002
    ..Further insights into the relationships between hemoglobin levels, patient well-being and symptoms may lead to a refinement of current strategies of approaching the treatment of anemia...
  29. pmc Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leuka
    Sergio Amadori
    Tor Vergata University Hospital, Rome, Italy
    Br J Haematol 149:376-82. 2010
    ..The day 1 + 8 schedule, which was associated with the highest rate of DnP, met the statistical criteria to be selected as the preferred regimen for phase III comparison with best supportive care...
  30. ncbi request reprint Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Blood 99:1578-84. 2002
    ..The optimal ATRA and EPO schedule and the role of maintenance treatment remain to be determined and warrant further investigation...
  31. doi request reprint Therapeutic strategies for hepatitis- and other infection-related immune thrombocytopenias
    Roberto Stasi
    Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Italy
    Semin Hematol 46:S15-25. 2009
    ..In other regions where these infections are not prevalent, such testing is controversial...
  32. ncbi request reprint Cancer-related fatigue: evolving concepts in evaluation and treatment
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Cancer 98:1786-801. 2003
    ..The lack of a standard of care for the assessment or treatment of fatigue in patients with cancer has limited research in this field. A critical appraisal of these issues is presented in this review...
  33. ncbi request reprint Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma
    Claudio M Pacella
    Regina Apostolorum Hospital, Department of Diagnostic Imaging and Interventional Radiology, Via San Francesco 50, Albano Laziale, Rome 00041, Italy
    Eur J Radiol 66:88-94. 2008
    ..To evaluate the feasibility, safety, and clinical benefits of percutaneous laser ablation (PLA) in patients with unresectable primary and metastatic adrenocortical carcinoma (ACC)...
  34. ncbi request reprint Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors
    Antonio Bruno
    Department of Immunohematology, University Tor Vergata, Bambino Gesu Hospital, Rome, Italy
    Transfus Apher Sci 26:103-10. 2002
    ..Positive selection of CD34+ cells seems to be related to the quality of the apheresis products, particularly to the initial CD34+ cell and PLT content...
  35. ncbi request reprint Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis
    Claudio Maurizio Pacella
    Department of Diagnostic Imaging and Interventional Radiology, Ospedale Regina Apostolorum, Rome, Italy
    J Vasc Interv Radiol 16:1447-57. 2005
    ..To identify the factors that affect the achievement of tumor necrosis with percutaneous laser ablation (PLA) in patients with hepatocellular carcinoma (HCC) and tumor size no larger than 4.0 cm...
  36. doi request reprint Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis
    Claudio Maurizio Pacella
    Department of Radiology and Diagnostic Imaging and Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy
    J Clin Oncol 27:2615-21. 2009
    ..Percutaneous laser ablation (PLA) has been proposed as an active treatment in patients with hepatocellular carcinoma (HCC). However, large multicenter studies using this technique have not been reported...
  37. pmc Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
    Franco Mandelli
    Department of Cellular Biotechnologies and Hematology, SapienzaUniversity, Rome, Italy
    J Clin Oncol 27:5397-403. 2009
    ..To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)...
  38. doi request reprint The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
    Giovanni Del Poeta
    Department of Haematology, Ospedale S Eugenio, University Tor Vergata, Rome, Italy
    Br J Haematol 149:383-7. 2010
    ..35 subset showed a very high CR rate (96%), very long OS (P = 0.00005) and disease-free survival (P = 0.004). The favourable prognosis of NPM1-mt/FLT3-ITD negative patients might be explained by a higher bax/bcl-2 ratio...
  39. doi request reprint Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia
    Sergio Amadori
    Department of Hematology, Tor Vergata University Hospital, Rome, Italy
    Curr Opin Hematol 15:95-100. 2008
    ..This review addresses use of monoclonal antibodies and immunoconjugates to treat acute myeloid leukemia...
  40. ncbi request reprint The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
    Nichola Cooper
    Division of Hematology Oncology, Departments of Pediatrics and Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, USA
    Br J Haematol 125:232-9. 2004
    ..No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP...
  41. ncbi request reprint Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges
    Roberto Stasi
    Blood 104:2201; author reply 2201-2. 2004
  42. ncbi request reprint Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
    Andre Bosly
    Cliniques Universitaires, Mont Godinne Yvoir, Belgium
    Anticancer Drugs 13:S25-33. 2002
    ..Available data thus indicate that rituximab can be an effective therapy in a wide range of CD20+ lymphoid disorders...
  43. ncbi request reprint [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study]
    Paola Meo
    Dipartimento di Ematologia, Ospedale S Eugenio, Universita Tor Vergata, Roma
    Recenti Prog Med 93:421-7. 2002
    ..In conclusion, we confirm that rituximab can induce long-lasting responses in patients with chronic ITP and has a favorable side effect profile. Therefore, we suggest its use in refractory ITP cases...
  44. ncbi request reprint Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Nichola Cooper
    Molecular Immunology Unit, Institute of Child Health, London, UK
    Curr Opin Hematol 14:642-6. 2007
    ..This review discusses whether the optimal timing for this therapy is before splenectomy, or after failure of splenectomy...
  45. ncbi request reprint Secondary immune thrombocytopenic purpura
    Howard A Liebman
    University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Curr Opin Hematol 14:557-73. 2007
    ..The guidelines did not address thrombocytopenia resulting from autoimmune disorders or chronic infections such as Helicobacter pylori, hepatitis C virus or HIV...
  46. ncbi request reprint Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura
    Roberto Stasi
    Blood 99:3872-3. 2002
  47. ncbi request reprint Monoclonal antibodies and immunoconjugates in acute myeloid leukemia
    Sergio Amadori
    Department of Hematology, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy
    Best Pract Res Clin Haematol 19:715-36. 2006
    ..Whether or not monoclonal antibody therapy will improve disease outcome compared with conventional treatment regimens remains to be demonstrated by well-designed clinical trials...
  48. ncbi request reprint Questions about anastrozole for early breast cancer
    Roberto Stasi
    Lancet 360:1890; author reply 1890-1. 2002
  49. pmc Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, P le dell Umanesimo, 10, 00144 Rome, Italy
    Blood 106:27-34. 2005
    ..2 vs 29.7 days; P < .001). We conclude that although priming with G-CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients...
  50. ncbi request reprint Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
    Drew Provan
    Department of Haematology, Bart s and The London, Queen Mary s School of Medicine and Dentistry, Whitechapel, London, UK
    Haematologica 92:1695-8. 2007
    ..The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients...